Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Radiation Therapy Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00238420 |
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Paclitaxel may also make tumor cells more sensitive to radiation therapy. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel together with radiation therapy and trastuzumab may kill more tumor cells. Giving these treatments after surgery may kill any remaining tumor cells.
PURPOSE: This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone surgery for bladder cancer.
Condition | Intervention | Phase |
---|---|---|
Bladder Cancer |
Biological: trastuzumab Drug: paclitaxel Radiation: radiation therapy |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized |
Official Title: | A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer |
Estimated Enrollment: | 88 |
Study Start Date: | July 2005 |
Estimated Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Group 1: Experimental
Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab (Herceptin®) IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Biological: trastuzumab
Given IV
Drug: paclitaxel
Given IV
Radiation: radiation therapy
Given once daily
|
Group 2: Experimental
Patients receive paclitaxel and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50.
|
Drug: paclitaxel
Given IV
Radiation: radiation therapy
Given once daily
|
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a non-randomized, multicenter study. Patients are assigned to 1 of 2 treatment groups according to HER2/neu status (HER2/neu 2+ or 3+ staining [group 1] vs HER2/neu 0 or 1+ staining [group 2]).
PROJECTED ACCRUAL: A total of 88 patients (44 per treatment group) will be accrued for this study within approximately 3 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed primary transitional cell carcinoma (TCC) of the bladder
Meets 1 of the following stage criteria:
Tumor involvement of the prostatic urethra allowed provided the following criteria are met:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, California | |
Auburn Radiation Oncology | Recruiting |
Auburn, California, United States, 95603 | |
Contact: Christopher Jones, MD 916-646-6600 | |
Mercy Cancer Center at Mercy San Juan Medical Center | Recruiting |
Carmichael, California, United States, 95608 | |
Contact: Christopher Jones, MD 916-646-6600 | |
Mercy General Hospital | Recruiting |
Sacramento, California, United States, 95819 | |
Contact: Christopher Jones, MD 916-646-6600 | |
Solano Radiation Oncology Center | Recruiting |
Vacaville, California, United States, 95687 | |
Contact: Christopher Jones, MD 916-646-6600 | |
Radiation Oncology Centers - Cameron Park | Recruiting |
Cameron Park, California, United States, 95682 | |
Contact: Christopher Jones, MD 916-646-6600 | |
Radiological Associates of Sacramento Medical Group, Incorporated | Recruiting |
Sacramento, California, United States, 95815 | |
Contact: Christopher Jones, MD 916-646-6600 | |
Radiation Oncology Center - Roseville | Recruiting |
Roseville, California, United States, 95661 | |
Contact: Christopher Jones, MD 916-646-6600 |
Study Chair: | M. Dror Michaelson, MD, PhD | Massachusetts General Hospital |
Investigator: | Alan Pollack, MD, PhD | Fox Chase Cancer Center |
Investigator: | Douglas M. Dahl, MD | Massachusetts General Hospital |
Responsible Party: | Radiation Therapy Oncology Group ( Walter John Curran, Jr ) |
Study ID Numbers: | CDR0000440988, RTOG-0524 |
Study First Received: | October 12, 2005 |
Last Updated: | September 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00238420 History of Changes |
Health Authority: | Unspecified |
stage I bladder cancer transitional cell carcinoma of the bladder stage II bladder cancer stage III bladder cancer |
Urinary Tract Neoplasm Cystocele Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Neoplasms Antimitotic Agents Carcinoma, Transitional Cell Urologic Neoplasms |
Carcinoma Urologic Diseases Paclitaxel Tubulin Modulators Trastuzumab Bladder Neoplasm Antineoplastic Agents, Phytogenic Transitional Cell Carcinoma |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Urinary Bladder Diseases Mitosis Modulators Urinary Bladder Neoplasms Urogenital Neoplasms Antimitotic Agents Urologic Neoplasms Pharmacologic Actions |
Neoplasms Neoplasms by Site Urologic Diseases Paclitaxel Therapeutic Uses Tubulin Modulators Trastuzumab Antineoplastic Agents, Phytogenic |